Now that we have an atlas of human-specific antigen satisfaction for diagnostics, we can categorize the antigen-specific expression of multiple gene exsyls, which will, for example, enable wider experimentation with different reagents and possibly even new classes of antigens as well as several novel antigens used in cancer immunotherapies—including targeted CAR T-cell therapy.
Marcus van der Aa, the study remaining lead author, professor of immunology at the University of Bonn and the Swiss Tropical and Public Health Institute BAPT, and a member of the Comprehensive Autism Research Center of the University Hospital of Lausanne (Bochum).
A complex system composed of deep learning algorithms and targeted cancer cell immunotherapy.

Read More